Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

No 666 Xinhua Avenue, Chengdu Cross-strait Science And Technology Industry Development Park, Wenjiang District, 611138

About the sponsor

Clinical research activity includes metastatic and locally advanced unresectable solid tumors that have progressed after standard therapies, with attention to treatment-resistant disease settings and tumour response in heavily pretreated populations.

  • Metastatic or locally advanced unresectable solid tumors
  • Tumors progressing after available standard therapies
  • Objective response in difficult-to-treat cancers

The sponsor’s oncology portfolio in this area reflects a strong interest in late-line cancer treatment across heterogeneous solid malignancies.

About Specializations

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. runs clinical trials in conditions such as Non-small cell lung cancer, Neoplasm malignant, Endometrial cancer, Transitional cell carcinoma, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

3 clinical trials

Non-small cell lung cancer

Not recruiting

Study of SKB264 and Pembrolizumab for Treating Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Carbonate
  • Sponsor:Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

Neoplasm malignant

Not recruiting

Study of SKB264 for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Carbonate
  • Sponsor:Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

Endometrial cancer+4

Not recruiting

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.